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ABSTRACT 
 
Background  
Cardiovascular disease is the leading cause of mortality in chronic kidney 
disease (CKD). Serum phosphate has been associated to cardiovascular 
disease in the general population and this effect seems to be different 
according to sex. In the present study we analyze the effect of phosphate on 
subclinical atherosclerosis in the NEFRONA population and its effect depending 
on sex. 
Design 
Carotid ultrasound assessing the presence of plaques was performed by an 
itinerant team in 1687 CKD patients not in dialysis without previous 
cardiovascular events. Standard blood test and anthropometrical parameters 
were also recorded. 
Results 
Multivariate linear regression to model phosphate levels in patients with CKD 
showed an interaction of sex with age. Thus, among men, serum phosphate 
levels declined significantly with age almost linearly. Serum phosphate levels in 
women under the age of 40-45 years overlapped with those in men and then 
stayed above, showing and overall constant relationship. Multivariate logistic 
regression analysis showed that higher phosphate levels associated with a 
higher risk of presenting atheromatous plaque. This risk however was different 
according to sex. In men, phosphate levels within the normal range associated 
with an increased risk of subclinical atheromatosis whereas in women this risk 
only increased with serum levels over the normal range. 
Conclusions 
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This study demonstrates that phosphate levels are associated with the 
presence of subclinical atheromatosis in a large CKD population. This effect of 
phosphate on subclinical atheromatosis was different according to sex, 
suggesting that a recommended serum phosphate levels could be different for 
male than for female CKD patients. 
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INTRODUCTION 
 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
the general population [1] as well as in patients with chronic kidney disease 
(CKD) [2, 3]. Beyond traditional cardiovascular risk factors like hypertension, 
diabetes and dyslipidemia, which underestimate the risk in CKD patients [4, 5], 
CVD in CKD is also associated with hyperphosphatemia [6].  
There is strong observational evidence showing that higher fasting serum 
phosphate levels are associated with a greater risk for cardiovascular disease in 
patients with CKD as well as in the general population [7-10]. Thus, in subjects 
with normal renal function, serum phosphate was positively associated with 
carotid intima-media thickness (cIMT) [11] and even with mortality [12] 
independently of traditional cardiovascular risk factors. The main mechanism 
involved in the pathophysiology of phosphate-induced cardiovascular risk is 
vascular calcification. However, high phosphate levels have been also 
associated with endothelial dysfunction [13, 14] which can increase the risk for 
atherosclerosis and hypertension [15, 16]. Thus phosphate may promote 
plaque development or rupture independently of its classical effects in vascular 
calcification [17]. 
The new guidelines on the assessment of cardiovascular risk [18] reiterate a 
key concept that has been known for decades, namely that men are at higher 
risk for cardiovascular disease than women independently of other known risk 
factors.  As it has been demonstrated with traditional cardiovascular risk factors, 
the association of serum phosphorus with subclinical and clinical CVD in the 
general population could be different in men than in women [19]. For instance, 
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in the ARIC study, a large community-based observational study of middle aged 
adults predominantly without CKD, high serum phosphorus levels were 
associated with cIMT and CV events only in men.  
On the basis of sex differences of phosphorus with subclinical and clinical CVD 
in the general population, we hypothesized that phosphorus levels would also 
be associated with greater asymptomatic atherosclerosis burden in CKD, and 
that this association would be different in men than in women. The results of 
this study show for the first time, that the effect of phosphate levels in the 
atherosclerosis burden of CKD patients differs according to sex. 
MATERIALS AND METHODS 
Patients 
Study population included 1687 chronic kidney disease patients not in dialysis 
from the Spanish Multicenter Study NEFRONA. The Nefrona study is an 
observational, prospective, multicenter 4-year study aimed to assess the 
predictive value of non-invasive imaging techniques and biomarkers on CV 
events and mortality in a large cohort of Spanish patients with CKD. This is an 
ancillary study of the NEFRONA study, which has been extensively described 
[20, 21]. 
Briefly, patients were sequentially enrolled from 81 different hospitals 
throughout Spain, referred by their nephrologist between October 2010 and 
June 2012. The study was approved by each local ethics committee and 
subjects were included after providing informed consent. The tests were 
sequentially carried out by three trained itinerant teams composed each one of 
one technician and one nurse. Patients were eligible for inclusion if they had 
CKD (glomerular filtration rate (GFR) < 60 ml/min per 1.73 m²) stages 3 to 5 
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not in dialysis and age between 18 and 74. Candidates were asymptomatic and 
without previous cardiovascular events at the time of recruitment. 
CKD stage was based on estimated GFR in ml/min per 1.73 m2, as determined 
by the four-variable Modification of Diet in Renal Disease (MDRD4) Study 
equation [22] and was categorized as stage 3 (GFR ≤60 ml/min and >30 
ml/min per 1,73 m2) and stage 4/5 (GFR ≤30 ml/min per 1.73 m2 without renal 
replacement therapy). 
Absence of cardiovascular disease was defined as absence of a history of 
coronary artery disease (myocardial infarction, coronary artery bypass graft 
surgery, coronary stent, or presence of stenosis on coronary angiography), 
heart failure (ejection fraction <45% or the presence of moderate or severe 
diastolic dysfunction by echocardiography) or peripheral arterial disease 
(claudication or vascular bypass surgery) or cerebrovascular disease (stroke).  
Phosphate levels were categorized in ranges of clinical significance as follows: 
0-3.5 mg/dl, 3.51-5 mg/dl and 5.1-10 mg/dl. Age was also categorized as 
follows: 18-45; 46-55; 56-65; >65 years. 
Smoking background included current as well as past history. Diabetes was 
defined as fasting glucose level ≥ 126 mg/dl or use of hypoglycaemic 
medication. Blood pressure was measured before the vascular exploration 3 
times in the seated position with a five minutes rest period between 
measurements with a validated semi-automatic oscillometer (Omron HEM-
705CP). The average of the second and third readings was recorded. 
Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic 
blood pressure ≥90 mmHg, or use of medications prescribed for hypertension. 
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Use of medications was based on clinical staff entry of prescriptions and 
confirmed with the patients. 
Body mass index (BMI) was calculated using the following equation: weight 
(kg)/height (m2). Biochemical blood test was obtained from fasting analysis in 
recent clinical records (within 3 months of the vascular ultrasound). 
Imaging methods 
All the participants in the study underwent the same carotid and femoral 
ultrasound protocol as previously described [23]. B-mode ultrasound imaging of 
the right and left carotid arteries was performed using a General Electric 
instrument (Vivid  BT09 model) equipped with 6-13 MHz broadband linear array 
transducers. This examination was used to measure cIMT to identify the 
presence of carotid plaques according to the Mannheim consensus [24]. Thus, 
cIMT equal or above 1.5 mm was considered as an atheroma plaque. The far 
wall of the common carotid, bulb and internal carotid arteries were scanned. 
We measured cIMT using the semiautomated U.S. Food and Drug 
Administration-approved software, EchoPAC Dimension (General Electric) 
based on detection of the echo structures. The ultrasounds were performed by 
the same itinerant team and were analysed by a unique reader in a blinded 
fashion. Femoral ultrasound was performed with the aim to identify 
atheromatous plaques in the common and superficial femoral arteries. 
Statistical analysis 
Fisher, Spearman, Mann-Whitney and Kruskal Wallis tests were conveniently 
used to evaluate the effect of baseline characteristics on phosphate levels. The 
use of these non-parametric tests was due to the lack of normality for most 
variables (not shown) but also for the reduced sample size. In addition, a 
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multivariate linear model was fitted to assess the joint effect of the clinical 
variables on phosphate levels. To study the risk factors associated to the 
presence of plaque a colour grid was used to represent the percentage of 
plaques as a function of age and phosphate levels. A multivariate logistic 
regression model was performed to globally assess the effects of all clinical 
variables, including phosphate levels, on the presence/absence of plaques. A 
stepwise procedure based on Akaike’s Information Criterion was used to 
determine the linear and logistic multivariate models. All the analyses were 
performed using R statistical package, setting the threshold for significance at 
5% (=0.05)  
 
RESULTS 
A total of 1687 CKD patients were considered for the analysis (906 stage 3, 
594 stage 4 and 187 stage 5). Mean age at study entry was 59.9 ±11.8 years; 
62.8% were males; 54.6% were current or former smokers; 28.5% were 
diabetics; 91% had hypertension; 71.1% had dyslipidaemia. 
The mean serum phosphate was significantly higher in women (3.88 ± 0.72 
mg/dl) than in men (3.62 mg/dl ± 0.8 mg/dl) (p<0.00001). 21% of the patients 
were on phosphate binders. Table 1 depicts the association of the serum 
phosphate level, using the intervals 0-3.5, 3.51-5 and 5.1-10 mg/dl, with the 
clinical variables, separately for men and women. Men showed a higher 
proportion of cases in the lowest range of phosphate while most women had 
phosphate levels higher than 3.5 mg/dl. Among men, those with phosphate 
level higher than 3.5 mg/dl were significantly younger. Mean cholesterol, LDL 
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and eGFR levels were significantly lower in men with a phosphate level higher 
than 5 mg/dl. Conversely systolic blood pressure was higher in this group of 
patients. The proportion of diabetics increased progressively in the three 
intervals considered. Among women, the proportion of smokers or former 
smokers was significantly lower for patients with phosphate levels between 
3.51 and 5 mg/dl. Mean eGFR levels decreased progressively along the three 
intervals considered. Systolic blood pressure was also positively correlated with 
phosphate levels.   
 
Factors associated with higher phosphate levels 
The multivariate linear analysis to model serum phosphate levels (Table 2) 
showed a significant effect of sex, diabetes, hypertension, age, eGFR and PTH 
and, more interestingly, revealed that sex significantly interacted with age and 
also that eGFR interacted with hypertension, PTH and cholesterol. More 
particularly, the interaction of sex and age with respect to phosphate levels is 
illustrated in Figure 1, showing that as age increased phosphate levels in men 
decreased (r=-0.19, p<0.00001) whereas in women phosphate levels were 
almost unchanged with age (r=-0.04, p=0.28). In this multivariate model, total 
cholesterol and BMI were not significantly associated with phosphate levels 
and were not included. 
 
Factors associated with the presence of atheroma plaque 
Regarding subclinical atheromatosis assessed by carotid and femoral 
ultrasound, 69.4% of patients had atheroma plaque. Figure 2 provides a 
representation of the percentages of plaque by age, phosphate levels and sex, 
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showing that atheromatous plaque risk clearly increases with age and with 
phosphate levels in all the intervals considered. In addition to this, Figure 2 also 
shows that for phosphate levels within the normal range (3.5 to 5 mg/dl) the 
risk of atheromatous plaque increased at younger ages for men than for 
women. As expected, classical cardiovascular risk factors were more prevalent 
in the group of patients with plaque, who were older (63.2±8.6 vs 50.8±13.6, 
p=<0.0001), had a higher prevalence of diabetes (81.1 vs 18.9%, p=<0.0001) 
and smoking background (75.8% vs 24.2%, p=<0.0001), higher values of 
systolic blood pressure (146.8±21.5 vs 139.7±19.6, p=<0.0001), BMI 
(29.4±4.98 vs 28.05±5.29, p=<0.0001), and lower concentrations of 
HDL(49.6±15 vs 51.5±16, p=0.022). We did not find a graded association 
between a reduced eGFR and the risk for the presence of plaque. In addition, 
no differences were found in the presence of plaque among CKD stages 
(59.8% stage 3; 69.1% stage 4 and 68.8% stage 5, p=0.87).  
Table 3 presents the results of the multivariate logistic regression model 
separately for each sex, categorizing age and phosphate levels as in the 
previous figure, showing that in men the classical cardiovascular risk factors 
(age, tobacco and diabetes) but also phosphate levels were significantly 
associated to plaque risk and, importantly, this effects were independent of 
glomerular filtration rate. Similar findings were found in women but the effect of 
the different ranges of phosphate was more prominent in the higher range. 
Further adjustment for phosphate binder use was not significant and did not 
modify the coefficients nor the p values. Figure 3 describe the effect of 
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phosphate levels on atheromatous plaque risk stratified by sex when adjusting 
by age, tobacco, diabetes, CRP and eGFR. A level of [3.5-5] mg/dl (within the 
normal range) of laboratory was associated in men to a higher risk of plaque 
when compared to the reference group with a phosphate level between [0-3.5] 
mg/dl and age between 18 and 45. However, in women a higher risk was only 
observed in the range between [5-10] mg/dl above the normal range of 
laboratory. The effect of age and phosphate levels was also significant when 
considered as continuous variables in the multivariate models (results not 
shown) for both sexes.  
 
DISCUSSION 
In our study we found that in community-living individuals with a range of kidney 
function from moderate to severe CKD, higher phosphate levels are significantly 
associated with a higher risk for atherosclerosis. This association is different 
according to sex, so that phosphate levels within the normal range are 
associated with atheromatosis only in men. 
In this study we have used the presence of plaque detected by ultrasound as an 
indicator of atheromatosis. Prior reports have demonstrated that carotid plaque 
and cIMT are highly correlated, and that each of them independently predicts 
cardiovascular events in non-CKD cohorts [25]. Furthermore, the presence of 
plaque seems to have an additive role to that of cIMT in estimating 
cardiovascular risk in the general population [26]. Similarly, studies in patients 
with CKD have been unable to find a difference between coronary artery 
calcification, carotid plaque, and cIMT in the ability to predict self-reported 
prevalent CVD [27]. Thus, the presence of plaque seems to be an effective 
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surrogate marker for predicting cardiovascular events. 
We have found that serum phosphate levels are associated with age, sex, the 
presence of diabetes and hypertension, the eGFR and levels of PTH and 
cholesterol. Interestingly, a strong interaction between sex and age was 
observed. Thus, as depicted in figure 1, serum phosphate levels declined with 
age almost linearly among men. In women under the age of 40-45 years, 
phosphate levels overlapped those in men and then were progressively higher. 
This effect remained when adjusting for variables known to affect phosphate 
levels as glomerular filtration rate and PTH. In this regard, it has been proven 
that phosphorus homeostasis is different in men and women [28]. The 
underlying mechanisms are uncertain, but there is evidence pointing to an 
effect of sex hormones in phosphate regulation [29]. Indeed, menopause and 
estrogen use affect serum phosphate concentrations [30]. 
As in the general population, traditional cardiovascular risk factors like smoking 
or diabetes remained associated with the presence of plaques. However 
phosphate levels were also related with the presence of subclinical 
atheromatous disease in our CKD population both, in men and women. 
However, serum phosphate seemed to have an effect on the presence of 
atheromatous plaque which was different as far as sex is considered. Thus in 
men, we found that fasting serum phosphate levels within the normal range 
were strong predictors of the presence of atheromatous plaque in CKD stages 3 
to 5, as it has been described in the general population [31]. However the 
increased risk in women is only observed with phosphate levels over the normal 
range. This finding is supported by recent evidence suggesting that the 
association between serum phosphate levels and subclinical and clinical CVD 
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in the general population may be different according to sex. [32] 
Whether serum phosphate is only a biomarker or a risk factor, is a question that 
remains to be elucidated. Thus, high FGF23 levels have been reported to be 
more strongly associated with vascular disease and mortality than serum 
phosphate levels. Furthermore, they were better predictors of adverse events in 
patients with normal serum phosphate [33]. In our study we did not determine 
FGF23 levels but, in any case, data are consistent with the hypothesis that 
higher phosphate levels are independent risk factors for atheromatous disease 
in CKD patients in which the contribution of other possible confounding factors 
has been ruled out. Furthermore, they provide important insights to delineate 
pre-clinical studies to conclusively establish whether the observed increases in 
atheromatosis result from a direct effect of elevations in serum phosphate or 
through phosphate activation of another pro-atheromatous mechanism. In turn, 
the identification of the pro-atheromatous mechanism induced by serum 
phosphate should help identify novel target for therapeutic interventions in 
individuals refractory to reductions in serum phosphate.  
Strengths of this study include the relatively large population encompassing 
nearly every region of the country. Therefore, local bias was avoided. 
Furthermore the carotid ultrasound was performed by a unique team and 
analysed by one reader in a blinded fashion, avoiding the well-known 
interoperator bias. 
However some limitations should be noted as the use of estimated GFR as 
opposed to direct measurement, the lack of a control group without CKD and 
the use of a surrogate marker instead of clinical outcome data. In addition, our 
study might suffer from a selection bias due to those patients who declined to 
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participate in the study, but this bias could not be assessed given that this 
information was not reported by the hospitals participating in this multicentric 
study. Besides, we relied on a single determination of serum phosphorus that 
may not accurately reflect time-averaged concentrations. In this regard, an 
isolated fasting morning serum phosphate measurement may underestimate 
24-hour exposure. Furthermore this study lacks measurements of 1,25 
hydroxyvitamin D or FGF23, which may be important mediators or confounders 
of the relationship between serum phosphate and the presence of 
atheromatous plaques [34-36]. The wide age range could also be considered a 
limitation of the study. However, in order to obtain an adequate sample size, the 
age range had to be widened. Thus, we have included pre and post-
menopausal women. The perimenopausal period, at least in the general 
population, has been associated to higher levels of serum phosphate [37]. As 
menopausal status has not been recorded, we could not determine if phosphate 
levels were higher in menopausal women. In addition, the fact that this is an 
ancillary study from the NEFRONA study adds some limitations in the sense 
that no cause and effect relationships can be assessed and, in addition 
confounding variables have been selected from the available ones in the 
protocol.  
In summary age, diabetes, smoking history and phosphate levels are variables 
significantly associated to atherosclerosis in CKD patients not in dialysis. 
Although phosphate levels within the normal range are associated to the 
presence of atheromatous plaque in men, this association is not found in 
women until they reach pathological levels. Due to this differential effect 
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regarding sex, recommended serum phosphate levels could be different for 
male than for female CKD patients 
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Figure legends 
 
Figure 1. Correlation of phosphorus with age by sex. Red and black dots 
represent women and men respectively. The regression line for each 
subpopulation is shown. 
 
Figure 2. Observed percentages of atheromatosis plaques (carotid and 
femoral) by age and phosphorus in women and men. Percentages are colored 
in a 0 to 100% green to red scale. 
 
Figure 3. Odds-ratios to evaluate the risk of atheromatosis depending on the 
phosphorus level, estimated by means of a logistic regression model adjusted 
by age, tobacco, diabetes, CRP and glomerular filtration rate. Reference 
category (OR=1) defined by those patients with phosphorus level between 0 
and 3.5 mg/dl and age between 18 and 45 years, for each sex group. Segments 
represent 95% confidence interval for ORs  
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Table 1. Association of clinical variables with intervals of phosphorus, stratified by 
sex.  
 
 Serum Phosphorus Level (mg/dl) 
P Value 
VARIABLE 0 - 3.5 3.51 - 5 5.1 - 10 
N of participants n/total (%)     
Men 545/1059 (51.4%) 462/1059 (43.7%) 52/1059 (4.9%)  
<0.00001 
 Women 211/628 (33.6%) 375/628 (59.97%) 42/628 (6.7%) 
Diabetes Mellitus Yes/no (%)     
Men 135 /409  (24.8%) 165/297 (35.7%) 22/31 (41.5%) <0.00001 
 
Women 48/163 (22.7%) 97/278 (25.9%) 13/29 (31.0%) 0.47 
Hypertension Yes/no (%)     
Men  489/55 (89.17%) 424/38 (91.40%) 51/2 (96.36%) 0.24 
Women 182/29 (86.3%) 347/28 (92.5%) 42/0 (100%) 0.004 
Dyslipidaemia Yes/no (%)     
Men  388/156 (71.3%) 337/125 (72.9%) 41/12 (77.4%) 0.48 
Women 140/71 (66.4%) 263/112 (70.1%) 30/12 (71.4%) 0.59 
Current or past smoking Yes/no (%)     
Men 396/148 (72.8%) 316/146 (68.4%) 40/13 (75.5%) 0.32 
Women 68/143 (32.2%) 85/290 (22.7%) 17/25 (40.5%) 0.01 
Age, years   Mean (SD)     
Men 62.4±9.7 58.2± 13 56.9±11.3 <0.00001 
Women                  58.6±12.9 59.8±11.9 56.3±11.3 0.15 
Body  mass index, kg/m2 Mean (SD)     
Men 29.04±3.9 28.4±4.6 28.7±5.19 0.06 
Women 29.36±6.4 29.64±6.2 28.79±6.81 0.66 
Total cholesterol, mg/dl Mean (SD)     
Men                  179.3±35.1 177.3±39 163.2±35.1 0.01 
Women                 194.7 ±35          191.7±37 196.3±38.4 0.53 
LDL cholesterol, mg/dl Mean (SD)     
Men                  105.7±31.7         101.8±33 89.1±30.7 0.002 
Women 112±32.1 108.9±33 109.6±28.1 0.56 
HDL colesterol, mg/dl Mean (SD)     
Men  46.4±12.9 45.6±13.6 45.2 ±22.1 0.70 
Women 57.3±14.3 56.2±15.4 57.8±17.6 0.66 
Triglycerides, mg/dl Mean (SD)     
Men 146.6 ±81 156.8 ±86 159.1±81.1 0.13 
Women 133.2 ±68 140.5±85 143.7±110 0.54 
eGFR (MDRD) Mean (SD)     
Men 39.8±12.1 29.1±13.4 16.34±9.6 0.000 
Women 36.7±12.4 28.8±12.7 15±5.8 0.000 
Sistolic Blood Pressure (mmHg)     
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 Serum Phosphorus Level (mg/dl) 
P Value 
VARIABLE 0 - 3.5 3.51 - 5 5.1 - 10 
Men 144.4±18.8 144.8±22 152.9±23.6 0.02 
Women 140.7±20.2 145.5±23 155.9±28.7 0.000 
Diastolic Blood Pressure (mmHg) 
 
    
Men  82.5±10 81.2±11.1 82.3±12 0.15 
Women 81.3±10.7 81.9±10.8 85.7±12.3 0.06 
Plaque presence  Yes/no(%)     
Men 419/125(77) 348/114(75.3) 42/11(79.2) 0.82 
Women 117/94(55.5) 230/145(61.3) 31/11(73.8) 0.03 
 
For categorical variables the frequencies and percentages are shown. For quantitative variables the mean and 
the standard deviation are provided. Low density lipoprotein (LDL); High-density lipoprotein (HDL); 
Glomerular filtration rate estimated with the abbreviated modification of diet in renal disease equation (eGFR). 
Differences in categorical variables were assessed by Chi square test. Differences in continuous variables were 
assessed by a Mann-Whitney test. 
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Table 2. Multivariate linear regression to model phosphorus levels.  
 
 
 Beta Standard error p-value 
Constant 4.33 0.29  
Sex (Women vs Man) -0.46 0.18 0.01 
Diabetes (Yes vs No) 0.18 0.04 <0.00001 
Hipertension (Yes vs No) 0.69 0.17 0.00005 
Age (years) -0.01 0.002 <0.00001 
eGFR (ml/min/1.73 m2) -0.016 0.008 0.03 
Total Cholesterol (mg/dl) -0.0007 0.001 0.52 
PTH (pg/ml) 0.001 0.0003 <0.00001 
Sex:Age interaction 0.009 0.003 0.0009 
eGFR:Hipertension interaction -0.016 0.004 0.0001 
eGFR:Total cholesterol interaction 0.00006 0.00003 0.049 
eGFR:iPTH interaction -0.00006 0.00001 <0.00001 
 
Multiple linear regression model determined with a stepwise procedure, considering all potential predictors and 
several interactions. Only variables with a significant effect or showing a potentially confounding influence in 
the model were maintained.  Adjusted coefficients in the model are shown with their respective standard errors 
and p-values. Multiple R-squared: 0.31; Adjusted R-squared: 0.30. eGFR: estimated glomerular filtration rate. 
iPTH: Intact parathyroid hormone. 
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Table 3. Multivariate logistic regression to model the presence of plaque at any territory, 
stratified by sex.  
 
 
Variable Men Women 
 OR 95% CI Z p-value OR 95% CI Z p-value 
Constant 0.09  -5.9  0.12  -5.3  
Age(45-55) 5.20 3.02-8.96 5.9 <0.00001 5.56 2.79-11.1 4.9 <0.00001 
Age(55-65) 13.23 8.0-21.9 10.1 <0.00001 13.61 6.93-26.8 7.6 <0.00001 
Age(65-80) 31.67 18.3-54.8 12.4 <0.00001 23.20 11.6-46.3 8.9 <0.00001 
Phosphorus (3.51-5) 1.62 1.09-2.43 2.4 0.02 1.13 0.75-1.70 0.6 0.57 
Phosphorus (5.1-10) 2.03 0.85-4.87 1.6 0.11 2.94 1.16-7.43 2.3 0.02 
Diabetes (yes vs no) 1.89 1.24-2.88 2.9 0.003 2.08 1.32-3.27 3.2 0.001 
Tobacco use (yes vs no) 2.42 1.68-3.47 4.8 <0.00001 1.92 1.21-3.07 2.8 0.006 
eGFR 1.01 0.99-1.02 1.1 0.27 0.99 0.98-1.01 -0.9 0. 33 
CRP 1.03 1.00-1.06 1.7 0.10 1.00 0.98-1.03 0.1 0.91 
 
Multiple logistic regression models determined with a stepwise procedure, considering all potential predictors 
and several interactions. Only variables with a significant effect or showing a potentially confounding influence 
in the model were maintained. Odds ratio, 95% confidence interval, Z values, defined as the estimated 
coefficients standardized by their standard error (beta/se(beta)) and p-values are provided. Age reference 
interval: 18-45 years; phosphorus reference interval: 0-3.5 mg/dl; diabetes and tobacco (yes/no), eGFR and 
CRP as continuous variables. eGFR: estimated glomerular filtration rate. CRP: C reactive protein.  
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